|
See related Leustatin inj[祿斯得停 注射劑] information |
|
|
|
製造商 |
Janssen-Cilag |
|
代理/經銷商 |
Janssen-Cilag |
|
成份 |
Cladribine |
|
適應症 |
Treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. |
|
用量 |
A single course of 0.09 mg/kg/day for 7 days by continuous IV infusion. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
注意事項 |
Hepatic or renal impairment. Pregnancy & lactation. Severe bone marrow suppression, including neutropenia, anemia & thrombocytopenia may occur. Careful hematological monitoring is recommended, especially during the first 4-8 weeks of therapy. |
|
不良反應 |
Fatigue, nausea, rash, headache, inj site reactions, myelosuppression, infection, fever.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Leustatin 注射劑 |
|
Leustatin 1 mg/1 mL x 10 mL |
|
|
|
Manufacturer: |
Janssen-Cilag |
|
Distributor: |
Janssen-Cilag |
|
|
|
|
|
